Idelalisib in CLL and iNHL

Video

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses treatment with idelalisib for chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL)

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses treatment with idelalisib for chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL).

Clinical Pearls:

  • Idelalisib is a PI3K-delta-specific inhibitor
  • Idelalisib demonstrated promising results in various trials in CLL and iNHL
  • Idelalisib has little side effects, is very well tolerated, and improves quality of life
Recent Videos
Related Content
Brexu-cel Achieves Strong CNS and Systemic Responses in Adult B-ALL Patients

Brexu-cel Achieves Strong CNS and Systemic Responses in Adult B-ALL Patients

Jordyn Sava
November 22nd 2024
Article

Ibrahim N. Muhsen, MD, evaluated the efficacy of brexu-cel in adult patients with central nervous system involvement in relapsed/refractory B-cell acute lymphoblastic leukemia.

Read More

Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

Rohit Gosain, MD;Rahul Gosain, MD
April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen

Improving Outcomes Using Ribociclib in High-Risk Node-Negative Breast Cancer

Improving Outcomes Using Ribociclib in High-Risk Node-Negative Breast Cancer

Jordyn Sava
November 21st 2024
Article

Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node involvement who were enrolled in the phase 3 NATALEE trial.

Read More

Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

Nichole Tucker;Cyrus M. Khan, MD
May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen

Optimizing Treatment in Myeloma With Biweekly Dosing of Talquetamab

Optimizing Treatment in Myeloma With Biweekly Dosing of Talquetamab

Jordyn Sava
November 20th 2024
Article

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple myeloma.

Read More

FDA Approves Revumenib in KMT2A-Rearranged Acute Leukemia

FDA Approves Revumenib in KMT2A-Rearranged Acute Leukemia

Jordyn Sava
November 15th 2024
Article

Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia.

Read More